Sensitivity, Specificity, PPV and NPV are computed on the ABIRISK validation cohort for each strategy
| Drug | AUC(ESPOIR) | AUC(ABIRA) | STRATEGY 1 (high confidence in response) | STRATEGY 2 (high confidence in non-response) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SensitivitY | Specificity | PPV | NPV | Sensitivity | Specificity | PPV | NPV | |||
| Overall TNFi | 0.72 | 0.65 | 18% | 91% | 76% | 42% | 90% | 30% | 67% | 67% |
| (0.68-0.73) | (0.54 - 0.75) | (10%-27%) | (82%-98%) | (54%-95%) | (32%-51%) | (83%-96%) | (18%-44%) | (58%-76% | (45%-86% | |
| Etanercept | 0.74 | 0.70 | 60% | 73% | 78% | 53% | 95% | 15% | 64% | 67% |
| (0.68-0.75) | (0.57- 0.82) | (44%-74%) | (55%-89%) | (63%-92%) | (36%-69%) | (88%-100%) | (4%-30%) | (52%-76%) | (20%-100%) | |
| Monoclonal anti-TNF antibodies | 0.74 | 0.71 | 37% | 95% | 92% | 50% | 90% | 40% | 69% | 73% |
| (0.69-0.77) | (0.55-0.86) | (20%-55%) | (83%-100%) | (73%-100%) | (35%-66%) | (78%-100%) | (19%-62%) | (54%-84%) | (44%-100%) | |